Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Thyroid Gland Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)Study completedNCT03573960
What this trial is testing

Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer

Who this might be right for
Thyroid Neoplasms
Eisai Pharmaceuticals India Pvt. Ltd 50
Testing effectiveness (Phase 2)Study completedNCT02244463
What this trial is testing

A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer

Who this might be right for
Anaplastic Thyroid CancerThyroid CancerDifferentiated Thyroid Cancer
Dana-Farber Cancer Institute 46
Not applicableUnknownNCT06062563
What this trial is testing

Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer

Who this might be right for
Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma
Peking Union Medical College Hospital 10
Testing effectiveness (Phase 2)UnknownNCT03199677
What this trial is testing

A Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer

Who this might be right for
Refractory Cancer
Chinese Academy of Medical Sciences 40
Testing effectiveness (Phase 2)UnknownNCT02041260
What this trial is testing

A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting

Who this might be right for
Differentiated Thyroid Cancer (DTC)Poorly Differentiated Thyroid Cancer
Thomas Jefferson University 43
Testing effectiveness (Phase 2)Study completedNCT02614495
What this trial is testing

Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma

Who this might be right for
Thyroid Carcinoma
Hutchison Medipharma Limited 66
Early research (Phase 1)Study completedNCT01413113
What this trial is testing

Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery

Who this might be right for
Recurrent Thyroid CancerStage IVA Follicular Thyroid CancerStage IVA Papillary Thyroid Cancer+4 more
University of Washington 6
Large-scale testing (Phase 3)UnknownNCT03048877
What this trial is testing

Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Cancer
Peking Union Medical College Hospital 118
Testing effectiveness (Phase 2)Study completedNCT03244956
What this trial is testing

Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer

Who this might be right for
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
Gustave Roussy, Cancer Campus, Grand Paris 40
Early research (Phase 1)Study completedNCT04462471
What this trial is testing

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Who this might be right for
Thyroid CarcinomaThyroid CancerThyroid Cancer, Follicular+3 more
Memorial Sloan Kettering Cancer Center 8
Testing effectiveness (Phase 2)Active Not RecruitingNCT04544111
What this trial is testing

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Who this might be right for
Thyroid CancerThyroid Cancer, FollicularPapillary Thyroid Cancer+4 more
Memorial Sloan Kettering Cancer Center 19
Large-scale testing (Phase 3)Study completedNCT01876784
What this trial is testing

Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Cancer
Genzyme, a Sanofi Company 238
Testing effectiveness (Phase 2)Ended earlyNCT00525135
What this trial is testing

Valproic Acid (Depakote ER) in Patients With Advanced Thyroid Cancer

Who this might be right for
Head and Neck Cancer
University of California, San Francisco 5
Not applicableNo Longer AvailableNCT05225259
What this trial is testing

Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor

Who this might be right for
Carcinoma, Non-Small-Cell LungThyroid Neoplasms
Eli Lilly and Company
Testing effectiveness (Phase 2)Study completedNCT00519896
What this trial is testing

Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer

Who this might be right for
Recurrent Thyroid CancerStage IVA Follicular Thyroid CancerStage IVA Papillary Thyroid Cancer+5 more
University of Washington 35
Very early researchLooking for participantsNCT06898437
What this trial is testing

Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer

Who this might be right for
Radioiodine Refractory Differentiated Thyroid Cancer
Peking Union Medical College Hospital 20
Large-scale testing (Phase 3)Looking for participantsNCT06860971
What this trial is testing

AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma

Who this might be right for
Thyroid Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 144
Testing effectiveness (Phase 2)UnknownNCT03300765
What this trial is testing

Trail Evaluating Apatinib With IMRT for Inoperable or Iodine Refractory Thyroid Cancer

Who this might be right for
Thyroid Cancer
Xiayun He, MD 20
Testing effectiveness (Phase 2)Ended earlyNCT03753919
What this trial is testing

Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial

Who this might be right for
Metastatic Thyroid Papillary CarcinomaMetastatic Thyroid Follicular CarcinomaMetastatic Thyroid Cancer
Grupo Espanol de Tumores Neuroendocrinos 79
Testing effectiveness (Phase 2)Study completedNCT02870569
What this trial is testing

Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 48
Next Page